Cytori Therapeutics Inc (CYTX)
(Delayed Data from NSDQ)
$0.29 USD
+0.02 (5.56%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.28 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.29 USD
+0.02 (5.56%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.28 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cytori Therapeutics (CYTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytori (CYTX) delivered earnings and revenue surprises of -246.15% and -59.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cytori Therapeutics (CYTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cytori (CYTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytori's Chemotherapy Candidate Gets Orphan Drug Status
by Zacks Equity Research
Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.
Cytori Therapeutics (CYTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cytori (CYTX) delivered earnings and revenue surprises of -20.41% and -37.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock?
by Zacks Equity Research
Investors in Cytori Therapeutics, Inc. (CYTX) need to pay close attention to the stock based on moves in the options market lately.
Cytori Scleroderma Study Two-Year Follow-Up Data Published
by Zacks Equity Research
Cytori Therapeutics (CYTX) announced the publication of two year follow-up data from the scleroderma study.